Mainland China
/C O R R E C T I O N -- Ranok Therapeutics/
In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ASCO 2026, issued 01-Jun-2026 by Ranok Therapeutics over PR Newswire, we are advised by the co...
2026-06-02 06:16
3621
Jianzhi Education Technology Announces Agreement with SeaArt AI, One of the World's Top 20 Generative AI Platforms
BEIJING, June 1, 2026 /PRNewswire/ -- Jianzhi Education Technology Group Company Limited (the "Company" or "Jianzhi") (NASDAQ: JZ), a leading EdTech company in China, today announced that it has entered into an agreement (the "Agreement") with SeaArt AI, one of the leading generative artificial ...
2026-06-01 22:00
3164
Redefine Everyday Comfort with Baseus Bowie MC2 Open-Ear Audio
SHENZHEN, China, June 1, 2026 /PRNewswire/ -- Baseus continues to push forward with innovative, comfortable clip-on designs. The new Bowie MC2 open-ear earbuds pair Grammy winner-recommended audio with an industry-first CloudComfort air-cushion design, introducing a revolutionary new approach to ...
2026-06-01 21:00
2034
U Power Hydro Data Joint Venture Receives "Data Center Power & Energy Solution" Recognition at DIF Awards 2026 in Thailand
BANGKOK, June 1, 2026 /PRNewswire/ -- U Power Limited (Nasdaq: UCAR) ("U Power" or the "Company"), a provider of AI-integrated solutions for next-generation energy grids and intelligent transportation systems, building on its proprietary UOTTA™ electric vehicle ("EV") battery-swapping technology,...
2026-06-01 21:00
2494
aulumu Launches G05 Pro Multi-Function Mag Kickstand
A compact magnetic stand engineered as an everyday urban utility toolkit SHENZHEN, China, June 1, 2026 /PRNewswire/ -- aulumu, the design-driven accessories brand renowned for blending futuristic aesthetics with practical engineering, today announced the G05 Pro Multi-Function Mag Kickstand. This...
2026-06-01 19:38
1717
PUDU Embodied Unveils the Next-Generation PUDU D7: Opening a New Chapter for Industrial Semi-Humanoid Robotics
SHENZHEN, China, June 1, 2026 /PRNewswire/ -- Pudu Robotics
2026-06-01 19:00
1981
Eason Technology Announces the Formation of New Subsidiary, Four Ele Industrial Intelligent Tech to Target Power Energy, Energy Networks and New Energy Storage Facilities Scenarios
HONG KONG, June 1, 2026 /PRNewswire/ -- Eason Technology Limited ("Eason" or the "Company") (NYSE American: DXF), today announced the launch of a new wholly owned subsidiary, Four Ele Industrial Intelligent Tech. The Company plans for Four Ele Industrial Intelligent Tech to extends its digital te...
2026-06-01 18:55
3396
Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic Areas
SILICON VALLEY, Calif. and BEIJING, June 1, 2026 /PRNewswire/ -- On May 29, 2026, Haisco Pharmaceutical Group Co., Ltd. ("Haisco") (Ticker Code: 002653) announced a licensing and research collaboration with Eli Lilly and Company ("Lilly") to develop innovative medicines across multiple therapeuti...
2026-06-01 17:50
2139
Hoymiles Introduces HiBattery 4020 Series of Plug-In Home Energy Storage to Bring Solar Safety and Intelligence to the Next Level
HANGZHOU, China, June 1, 2026 /PRNewswire/ -- Hoymiles announced the official launch of its new HiBattery 4020 Series, the third-generation of its plug-in home battery system. The series features Hoymiles first hybrid model HiBattery 4020 X which is directly connected to PV modules, and the AC-co...
2026-06-01 15:05
2692
China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDA
BEIJING, June 1, 2026 /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical Group, has officially received marketing approval from the U.S. Food and Drug Administration (FDA), becoming ...
2026-06-01 15:04
2117
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
SHANGHAI, June 1, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology conferences, the ASCO Annual Meeting serves as a key venue for presenting advances in cancer r...
2026-06-01 13:51
2730
Unitree Announces H2 Plus, an NVIDIA Isaac GR00T Reference Humanoid Robot for Academic Research
News Summary: * Unitree Robotics introduces H2 Plus, an NVIDIA Isaac GR00T Reference Humanoid Robot combining a Unitree H2 humanoid robot, Sharpa five-fingered hands for dexterous manipulation, NVIDIA Jetson Thor for advanced reasoning and control, and the new NVIDIA Isaac GR00T development pl...
2026-06-01 13:30
2248
XPENG Announces Vehicle Delivery Results for May 2026
GUANGZHOU, China, June 1, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading global AI mobility technology company, today announced its vehicle delivery results for May 2026. XPENG delivered a total of 32,158 vehicles in May, representing a 4% increas...
2026-06-01 12:47
2687
Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, todayannounced updated clinical data from its Phase I/II study evaluating ...
2026-06-01 12:00
3984
ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
CHICAGO, May 31, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate (ORR) in patients with Late-line refractory hepatoce...
2026-06-01 10:37
3614
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product ca...
2026-06-01 08:15
2114
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved anobjective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benef...
2026-06-01 08:15
2366
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
SUZHOU, China, May 31, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As of the data cut-off o...
2026-06-01 08:00
1824
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
* IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR ...
2026-06-01 08:00
1632
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
* After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC * IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communication...
2026-06-01 08:00
2171
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 316 media titles]
2026-05-28 15:06Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 290 media titles]
2026-05-27 09:16
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 290 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 290 media titles]
2026-05-28 10:06Patong Stay & Dine Package at Courtyard by Marriott Phuket, Patong Beach Resort
[Picked up by 285 media titles]
2026-05-28 14:10
Most Read
Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
2026-05-27 09:16
6972
Creality Charts Next Decade as AI-Powered Consumer 3D Creative Platform, Hong Kong listing anchors the company's full-stack ecosystem shift
2026-05-30 11:58
6895
NYSE Content Update: Hinge Health Shares Up 72% One Year from its IPO
2026-05-28 21:14
6787
